<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04684394</url>
  </required_header>
  <id_info>
    <org_study_id>GEM-CL-10311</org_study_id>
    <nct_id>NCT04684394</nct_id>
  </id_info>
  <brief_title>A Multiple Dose Study of Repeat Intravitreal Injections of GEM103 in Neovascular Age-related Macular Degeneration</brief_title>
  <official_title>A Multicenter, Multiple-Dose Study in Neovascular Age-related Macular Degeneration (nAMD) to Evaluate the Safety, Tolerability, Pharmacodynamics, Immunogenicity, and Clinical Effect of Repeat Intravitreal (IVT) Injections of GEM103 as an Adjunct to Standard of Care Aflibercept Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemini Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gemini Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to investigate the safety and tolerability of GEM103 IVT injection +&#xD;
      standard of care vs. sham + standard of care.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2a, multi-center, multiple dose study in subjects with Neovascular&#xD;
      Age-related Macular Degeneration (nAMD) to investigate the safety and tolerability of GEM103&#xD;
      IVT injection + standard of care vs. sham + standard of care.&#xD;
&#xD;
      Subjects will undergo clinical and ophthalmic assessments for determination of inclusion in&#xD;
      the study and who meet all eligibility criteria will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 29, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of GEM103 as measured by treatment-related intraocular AEs</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>2. Pharmacokinetics, as measured by total CFH in aqueous humor after GEM103 IVT injection, whenever possible.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Describe the effect on vision, as measured by mean change in BCVA from baseline in ETDRS letters.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>4. Describe the effect on macular atrophy size as measured by mean change from baseline, evaluated by FAF.</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Neovascular Age-related Macular Degeneration</condition>
  <condition>Retinal Disease</condition>
  <condition>Retinal Degeneration</condition>
  <condition>Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>GEM103 + SoC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham+SoC</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GEM103</intervention_name>
    <description>Drug: GEM103 Biological</description>
    <arm_group_label>GEM103 + SoC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sham + SoC</intervention_name>
    <description>SoC defined as 2 mg aflibercept EOM</description>
    <arm_group_label>Sham+SoC</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. At least 50 years old at the time of signed informed consent&#xD;
&#xD;
             a. CNV related to nAMD, with maximum CNV lesion size is 12 disc area and subretinal&#xD;
             hemorrhage ≤50% of lesion size&#xD;
&#xD;
          2. On aflibercept treatment at enrollment&#xD;
&#xD;
          3. BCVA in the study eye of 24 to 75 letters using the ETDRS Chart VA Scale&#xD;
             (approximately equivalent to Snellen VA of between 20/32 and 20/320)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of the following ocular conditions in the study eye:&#xD;
&#xD;
               1. Any active ocular disease or condition that could confound the assessment of the&#xD;
                  macula or be a contraindication to IVT injection, severe glaucoma, ocular&#xD;
                  infection of any nature, diabetic retinopathy graded as moderate nonproliferative&#xD;
                  diabetic retinopathy or worse (with or without diabetic macular edema)&#xD;
&#xD;
               2. Any intraocular surgery,&#xD;
&#xD;
               3. Aphakia or complete absence of the posterior capsule&#xD;
&#xD;
               4. Prior corneal transplant&#xD;
&#xD;
               5. Scar or fibrosis ≥50% of lesion or involving center of fovea&#xD;
&#xD;
          2. Presence of any of the following ocular conditions - in either eye:&#xD;
&#xD;
               1. History of herpetic infection, idiopathic polypoidal choroidal vasculopathy&#xD;
                  (PCV), pathologic myopia, central serous chorioretinopathy (CSCR), adult onset&#xD;
                  foveal pattern dystrophy&#xD;
&#xD;
               2. Concurrent disease that could require medical or surgical intervention during the&#xD;
                  study period&#xD;
&#xD;
               3. Active/suspected ocular/periocular infection or active intraocular inflammation&#xD;
&#xD;
               4. History of idiopathic or autoimmune-associated uveitis&#xD;
&#xD;
          3. Subject has experienced a cardiovascular or cerebrovascular event within 12 months of&#xD;
             informed consent&#xD;
&#xD;
          4. Female subjects must not be pregnant or lactating, nor plan to become pregnant during&#xD;
             the study&#xD;
&#xD;
          5. Current use of medications known to be toxic to the lens, retina, or optic nerve&#xD;
&#xD;
          6. Use of any investigational new drug or other experimental treatment in the last 6&#xD;
             months, and/or receipt of any prior gene therapy (e.g. Adeno- associated virus) or&#xD;
             ocular device implantation (other than posterior chamber intraocular lens placement&#xD;
             after cataract surgery)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Arizona Retina and Vitreous Consultant</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Diagnostic Center of Northern California</name>
      <address>
        <city>Campbell</city>
        <state>California</state>
        <zip>95008</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Partners</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salehi Retina Institute</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Eye Specialists Medical Group</name>
      <address>
        <city>Pasadena</city>
        <state>California</state>
        <zip>91107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedEye Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Associates of Pinellas</name>
      <address>
        <city>Pinellas Park</city>
        <state>Florida</state>
        <zip>33782</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarasota Retina Institute</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Florida Eye Institute</name>
      <address>
        <city>Stuart</city>
        <state>Florida</state>
        <zip>34994</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid Atlantic Retina Specialists</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Asociates, Pc</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Neuroscience Center Building</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Carolina Retinal Associates</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charlotte Eye Ear Nose and Throat Associates PA</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sterling Research Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oregon Retina LLP</name>
      <address>
        <city>Eugene</city>
        <state>Oregon</state>
        <zip>97401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research of Beaufort</name>
      <address>
        <city>Beaufort</city>
        <state>South Carolina</state>
        <zip>29902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Retina Associates</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retinal Consultants of San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center Ophthalmology Associates</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78247</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>December 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 24, 2020</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
    <mesh_term>Wet Macular Degeneration</mesh_term>
    <mesh_term>Retinal Diseases</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

